Antidepressants

OCD Treatment with Antidepressants (SSRIs) Alters Brain Structure & Functions (2024 Study)

by

Antidepressant treatment in OCD is linked to structural and functional brain changes, particularly in corticosubcortical areas, but these findings need further validation in larger, more homogeneous samples. Highlights: Antidepressant Use: Antidepressants, especially SSRIs, are a primary treatment for OCD, resulting in significant brain changes. Brain Structure Changes: Studies show volume alterations in the thalamus, amygdala, …

Read more

Selegiline Reverses Anxiety & Memory Impairment in Amyloid Beta-Induced Alzheimers Model Rats (2024 Study)

by

The study demonstrated that selegiline (SEL) improves memory performance, reduces anxiety, and modulates oxidative stress in an Alzheimer’s disease (AD) rat model. Highlights: Memory Improvements: SEL administration improved recognition memory, spatial memory, and passive avoidance memory in AD rats. Anxiety Reduction: SEL significantly reduced anxiety-like behavior in AD rats, as evidenced by performance in the …

Read more

Ketamine Rapidly Reverses Suicidal Ideation & Severe Depression (2024 Meta-Analysis)

by

Ketamine significantly reduces suicidal ideation in depressed patients, with rapid effects observed within the first day of treatment. Highlights: Rapid Reduction: Ketamine shows a significant reduction in suicidal ideation within the first day of treatment (RR = 10.02, 95% CI = 4.24 to 23.68). Sustained Improvement: Repeated ketamine treatments result in a greater reduction of …

Read more

Repurposing General Anesthetic Drugs to Treat Depression: Ketamine, Nitrous Oxide, Propofol, Isoflurane (2024 Research)

by

Repurposing general anesthetic drugs like ketamine for the treatment of major depression represents a significant medical advancement – showcasing rapid and sustained antidepressant effects. Highlights: Rapid Antidepressant Effects: Ketamine, nitrous oxide, propofol, and isoflurane have shown rapid and sustained antidepressant properties, offering new treatment options for major depressive disorder and treatment-resistant depression. Mechanisms of Action: …

Read more

Allopregnanolone vs. Diazepam: Antidepressant Effects via Brain Activity Modulation (2024 Mouse Study)

by

Allopregnanolone shows antidepressant-like effects in mice by increasing social interaction and specific brain wave activities, unlike diazepam. Highlights: Allopregnanolone: Allopregnanolone, a neuroactive steroid, increases social interaction time in mice experiencing social defeat stress, indicating potential antidepressant-like effects. Brain Activity: This increase in social interaction is associated with heightened theta and beta oscillations in the basolateral …

Read more

Moderate Alcohol Intake Increases Depression Relapse in Men on SNRIs (2024 Study)

by

Moderate alcohol intake in men treated with SNRI antidepressants significantly increases the risk of depression relapse, according to a new study. Highlights: Risk Increase with SNRIs: Men with moderate alcohol consumption and elevated liver enzymes are significantly more likely to relapse when treated with serotonin-norepinephrine reuptake inhibitors (SNRIs). Sex Differences: Men generally had higher alcohol …

Read more

Lactofem Probiotic May Boost SSRI Efficacy & Counteract Sexual Side Effects in Women with Depression (2024 Trial)

by

Probiotics may help improve sexual function and reduce depression severity in women treated with SSRIs. Highlights: Depression Prevalence: Approximately 5% of all adults will experience depressive disorder, often accompanied by reduced sexual desire and dysfunction. Study Design: The study was a double-blind randomized clinical trial involving 112 women with depressive disorder treated with SSRIs, comparing …

Read more

How Common Are Antidepressant Withdrawal Symptoms? Estimated in 31% of Patients (2024 Review)

by

Antidepressant withdrawal symptoms occur in about one-third of patients stopping antidepressants, with severe symptoms in about 3% of cases – according to a new Lancet Psychiatry review. Highlights: Incidence of Symptoms: Approximately 31% of patients experience at least one discontinuation symptom after stopping antidepressants, compared to 17% for those stopping placebo. Severe Symptoms: Around 3% …

Read more

Quercetin Alginate Nanogels Loaded with BDNF for Depression (2023 Study)

by

TLDR: Quercetin-based alginate nanogels loaded with brain-derived neurotrophic factor (BDNF) can effectively cross the blood-brain barrier via intranasal delivery, providing a promising treatment for depressive disorders. Highlights: Nanogels: Quercetin nanogels protect BDNF from oxidative damage, exhibit rapid brain distribution, and significantly enhance bioavailability compared to oral administration. Efficacy: BDNF-Quercetin nanogels delivered via intranasal route show …

Read more

Esketamine Nasal Spray Rapidly Treats Depression & Suicidal Ideation (2023 Study)

by

TLDR: Esketamine nasal spray, combined with standard antidepressant therapy, significantly improves remission rates and reduces time to remission in adults with major depressive disorder (MDD) and acute suicidality compared to standard care alone. Highlights: Remission Rates: Patients treated with esketamine plus standard of care had higher remission rates than those treated with placebo plus standard …

Read more

+ Load more